Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines

Author:

Dabaja Bouthaina Shbib1ORCID,Hoppe Bradford S.2,Plastaras John P.3,Newhauser Wayne4,Rosolova Katerina56,Flampouri Stella2,Mohan Radhe7,Mikhaeel N. George8,Kirova Youlia9,Specht Lena10,Yahalom Joachim11

Affiliation:

1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;

2. Department of Radiation Oncology, University of Florida, Jacksonville, FL;

3. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA;

4. Department of Radiation Physics, University of Louisiana, Baton Rouge, LA;

5. Proton Therapy Department, Proton Therapy Center Czech, Prague, Czech Republic;

6. Department of Oncology, Charles University in Prague and Motol University Hospital, Prague, Czech Republic;

7. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX;

8. Department of Radiation Oncology, Guy's and St. Thomas' Hospital, London, United Kingdom;

9. Department of Radiation Oncology, Institut Curie, Paris, France;

10. Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; and

11. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

Abstract

Abstract Among adult lymphoma survivors, radiation treatment techniques that increase the excess radiation dose to organs at risk (OARs) put patients at risk for increased side effects, especially late toxicities. Minimizing radiation to OARs in adults patients with Hodgkin and non-Hodgkin lymphomas involving the mediastinum is the deciding factor for the choice of treatment modality. Proton therapy may help to reduce the radiation dose to the OARs and reduce toxicities, especially the risks for cardiac morbidity and second cancers. Because proton therapy may have some disadvantages, identifying the patients and the circumstances that may benefit the most from proton therapy is important. We present modern guidelines to identify adult lymphoma patients who may derive the greatest benefit from proton therapy, along with an analysis of the advantages and disadvantages of proton treatment.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3